SAMSUNG-BIOEPIS
10.9.2019 14:02:09 CEST | Business Wire | Press release
Samsung Bioepis Co., Ltd. today announced its expansion into the Brazilian biopharmaceutical market. The first product available in the country is BRENZYS™ (etanercept), a biosimilar referencing ENBREL® .i BRENZYS™ was approved by Agência Nacional de Vigilância Sanitária (ANVISA), the country’s health regulatory agency, in December 2017 for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and non-radiographic axial spondyloarthritis.
Samsung Bioepis is continuing its business expansion in multiple markets across the world, including mainland China, where the company entered into partnerships with 3SBio and C-Bridge Capital to develop and commercialize multiple biosimilar candidates from Samsung Bioepis.
BRENZYS™ is being supplied to Sistema Único de Saúde (SUS), the country’s public health system, through a Productive Development Partnership (PDP) between Samsung Bioepis and local partners, Bionovis and Bio-Manguinhos/Fiocruz.
Under the PDP, Samsung Bioepis will supply biosimilar products or product intermediaries to the local partners for sale to SUS for a period of 10 years. During this period, Samsung Bioepis will provide technology transfer to the local partners, so that manufacturing responsibilities can be gradually transferred to enable local manufacturing in Brazil. The PDP scheme was introduced by the Brazilian government in 2008, in order to expand access to medicines and support the country’s pharmaceutical industry through technology transfer from established companies in return for guaranteed purchases from SUS.
In Brazil, over 75% of patients nationwide rely on SUS for health care coverage.ii While biologics represent approximately 4% of all medicinal products acquired by SUS, they account for approximately 51% of government spending on medicinal products.iii
“We are excited to provide our high-quality biosimilars to patients across Brazil, and look forward to working with our local partners to enhance patient access to high-quality healthcare. Equally important, by sharing our scientific knowledge with our local partners, we hope to do our part in contributing to the long-term development of the Brazilian biopharmaceutical industry,” said Sang-Jin Pak, Senior Vice President and Head of Commercial Division, Samsung Bioepis. “At Samsung Bioepis, we will continue to demonstrate our enduring commitment to biosimilars by further strengthening our pipeline and widening their availability for patients and health care systems across the world.”
Samsung Bioepis’ products are now available across five continents: North America, Europe, Asia, Oceania, and Latin America. The company currently has four biosimilars approved and marketed across Europe, which include the anti-TNF trio of BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab), as well as an oncologic biosimilar, ONTRUZANT® (trastuzumab). Over 170,000 patients are currently under treatment with Samsung Bioepis’ biosimilars in Europe. In the United States, the company has one biosimilar – RENFLEXIS® (infliximab-abda) – approved and marketed. ONTRUZANT® (trastuzumab-dttb) received approval from the U.S. Food and Drug Administration (FDA) in January 2019, while ETICOVO™ (etanercept-ykro) and HADLIMA™ (adalimumab-bwwd) received FDA approval in April and July 2019, respectively.
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com .
_____________________________
i
ENBREL is a registered trademark of Pfizer
ii
Jurberg C, Humphreys G. Brazil's march towards universal coverage. Bull World Health Organ
. 2010;88(9):646-7.
iii
Debiasi M, et al. Biosimilars in Brazil: The Beginning of an Era of Broader Access. Journal of Cancer Therapy
. 2017; 8:814-826.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005444/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Elydan Acquieres Radpol Pipes in Poland Expanding Its Offering to Accelerate the Decarbonization of Europe's Energy Infrastructure22.9.2026 14:24:00 CEST | Press release
ELYDAN Group, specialist in water and energy network solutions, announces the acquisition of Radpol Pipes, a Polish industrial company specializing in the manufacture of pre-insulated piping systems for district heating and cooling networks. The acquisition expands Elydan’s capabilities in low-carbon energy infrastructure. The Group is entering a new phase of its European development with more than €250 million in revenue and 600 employees across 7 European countries. Expanding in Europe market driven by decarbonization and energy sovereignty “With Radpol Pipes, we are adding the technological expertise needed to cover the full range of district heating and cooling networks. This acquisition reflects a very concrete ambition: to provide our customers with the most comprehensive solutions to accelerate the decarbonization of infrastructure and contribute to Europe’s energy sovereignty. It is also a key milestone in our Momentum 2030 strategy, reinforcing our ambition to build a leading
ADX and Its Listed Companies Connect with International Capital at Global Investor Roadshow in New York22.9.2026 14:01:00 CEST | Press release
14 ADX-listed companies will present their growth strategies and equity stories to international investors The Abu Dhabi Securities Exchange (ADX) Group is heading to New York for its annual Global Investor Roadshow and Conference, held in collaboration with Morgan Stanley on 24 and 25 September 2026. This is part of ADX’s ongoing commitment and engagement outreach to institutional investors across key global financial centers. The ADX event in New York will highlight the investment opportunities Abu Dhabi’s capital markets offer through its leading listed companies, as the ADX supports Abu Dhabi’s long-term economic vision and sustainable economic growth as a global capital hub. H.E. Ghannam Butti Almazrouei, Chairman of the ADX, and Abdulla Salem Alnuaimi, Group Chief Executive Officer, will lead the delegation. They will be joined by senior management and investor relations officers from 14 ADX-listed companies. Direct discussions with management teams will enable investors to explo
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial22.9.2026 14:00:00 CEST | Press release
– In people with AMKD with modest proteinuria, treatment with inaxaplin led to a reduction in urine albumin to creatinine ratio (UACR) of -42.7% at Week 13 compared to baseline –- In people with AMKD and type 2 diabetes, treatment with inaxaplin led to a reduction in UACR of -17.3% at Week 13 compared to baseline –- Inaxaplin was generally safe and well tolerated in both cohorts –- Vertex has completed enrollment in the AMPLITUDE trial and remains on track for interim analysis results in early 2027, which, if positive could support potential accelerated approval in the US - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes. In this study, inaxaplin was evaluated as a 45 mg once-daily dose on top of optimized standard of care. Forty-one people were enrolled and dosed in two cohorts: 1) peop
INNIO Receives Credit Rating Upgrades and Reaffirms Financial Policy to Support Profitable Growth22.9.2026 14:00:00 CEST | Press release
INNIO N.V. (Nasdaq: INIO) (“INNIO” or the “Company”) today announced that Fitch Ratings has upgraded the Company’s credit ratings, following a recent upgrade by Moody’s Ratings. INNIO also reaffirmed its financial policy framework, which supports investment in profitable growth while continuing to strengthen the Company’s balance sheet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922051908/en/ INNIO Receives Credit Rating Upgrades and Reaffirms Financial Policy to Support Profitable Growth Credit rating upgrades Moody’s upgraded INNIO’s Corporate Family Rating by one notch to Ba3 from B1 and revised the outlook to positive from stable. Fitch Ratings upgraded INNIO’s Long-Term Issuer Default Rating by two notches to BB from B+, with a stable outlook. Fitch also upgraded INNIO’s senior secured debt rating to BB+ from B+. These upgrades reflect INNIO’s strong operating performance and cash flow generation, supported by fa
Who Decides What’s Safe Online? Trust Issues Returns for Season 222.9.2026 14:00:00 CEST | Press release
WebPurify, an IntouchCX Company specializing in trust and safety, has launched the season 2 of Trust Issues, a podcast exploring the technology, policies, and human decisions shaping the future of online safety. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922209613/en/ WebPurify, an IntouchCX Company specializing in trust and safety, has launched the season 2 of Trust Issues, a podcast exploring the technology, policies, and human decisions shaping the future of online safety. Who ultimately decides what stays up and what comes down in digital spaces? Season 2 answers that question by examining how AI capabilities, shifting market place regulations, human judgement and operational constraints intersect. Moving beyond simple technical solutions, each episode goes behind the scenes of the complex pressures facing digital platforms today, from cost efficiencies to high stake compliance, and the strategies leaders use to b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom